BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genaissance Pharmaceuticals, Inc. (GNSC) Invites You To Participate In Its Fourth Quarter 2004 Conference Call


10/19/2005 5:12:37 PM

NEW HAVEN, Conn., Feb. 3 /PRNewswire-FirstCall/ -- Genaissance Pharmaceuticals, Inc. today announced that the Company would conduct a conference call on Thursday, February 10, 2005, at 11:30 a.m. Eastern time (ET), in conjunction with the release of its financial results for the fourth quarter ended December 31, 2004.

"The past year's activities have put us in a strong position to achieve major objectives in our partnering and portfolio development programs," said Kevin Rakin, President and Chief Executive Officer of Genaissance. "The revenue growth we expect in 2005 should narrow our losses and potentially bring us to positive operating cash flow by the fourth quarter, based on current levels of program funding."

To participate in this conference call, dial 913-981-5510, confirmation code 2415972, shortly before 11:30 a.m. ET. A replay of the call will be available from 2:30 p.m. ET through midnight Wednesday, February 16, 2005. The replay number is 719-457-0820, confirmation code 2415972.

Genaissance Pharmaceuticals, Inc. is developing innovative products based on its proprietary pharmacogenomic technology and has a revenue-generating business in DNA and pharmacogenomic products and services. Genaissance also markets its proprietary FAMILION(TM) Test, designed to detect mutations responsible for causing Familial Long QT and Brugada Syndromes, two causes of sudden cardiac death. The Company's product development strategy is focused on drug candidates with promising clinical profiles and finding genetic markers to identify a responsive patient population. This strategy enables Genaissance to leverage existing clinical data and, thus, reduce the costs and risks associated with traditional drug development and increase the probability of clinical success and commercialization. The Company's lead therapeutic product, vilazodone for depression, is in Phase II of development. For more information on Genaissance, visit our website at: http://www.genaissance.com/.

Genaissance Pharmaceuticals, Inc.

CONTACT: Rhonda Chiger, of Rx Communications Group, +1-917-322-2569,rchiger@RxIR.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES